Company / Operating Cash Flow
Lexaria Bioscience Corp. Operating Cash Flow History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$5.0M
FY2025
5-year range
-$5.9M / -$2.6M
FY2021-FY2025
Trend
+15.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$5M.
Based on SEC 10-K filings.
-$5M in FY2025.
Remained stable around -$5M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 15.7% year-over-year.
- Peak operating cash flow was recorded in FY2015.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.0M | +15.7% |
| FY2024 | -$5.9M | -20.5% |
| FY2023 | -$4.9M | -22.3% |
| FY2022 | -$4.0M | -52.3% |
| FY2021 | -$2.6M | +12.9% |
| FY2020 | -$3.0M | -19.4% |
| FY2019 | -$2.5M | -281.0% |
| FY2017 | -$660.9K | +56.0% |
| FY2016 | -$1.5M | -191.0% |
| FY2015 | -$515.8K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026